Home Overview Press Room Blog Publications For Students about us
Search

Biotech & Pharma : Displaying 744-753 of 1970


23andMe's Designer Baby Patent is 'a Serious Mistake,' Critics Charge [Quotes CGS's Marcy Darnovsky]by Karen KaplanLos Angeles TimesOctober 3rd, 2013What’s even more repulsive than the idea of using DNA tests to help people create a designer babies? Getting a patent for the idea.
The Damaging Language of “Cure” and Down Syndromeby Amy Julia BeckerPatheosOctober 2nd, 2013Once again we’re hearing news of a breakthrough in research on drug therapies to enhance the cognitive processing of people with Down syndrome. And once again, the discussions seem to fixate on the controversial notion of a “cure.”
Feds Looks at Plan to Collect DNA from Suspects upon Arrest by Kim MackraelThe Globe and MailOctober 2nd, 2013Canada is considering a move to collect DNA samples from suspects upon arrest for certain crimes, raising concerns for criminal defence lawyers and civil-rights advocates.
Genetic Testing to be Easier Under Obamacareby Veronica LinaresUPI.comOctober 2nd, 2013Genetic testing for breast and ovarian cancer will be a lot easier under the Affordable Care Act.
Dangerous Workby EditorialNatureOctober 2nd, 2013Behavioural geneticists must tread carefully to prevent their research being misinterpreted.
[VIDEO] Debating Embryonic Genetic Testing[With CGS Advisory Board member Francine Coeytaux]The DoctorsOctober 1st, 2013New genetic tests, including Next Generation Sequencing, can radically improve the odds of a healthy, full term pregnancy … but where do we draw the line? Hear more from The Doctors.
California's $70 Million Alpha Stem Cell Clinic Plan Edging Forward by David JensenCalifornia Stem Cell ReportSeptember 30th, 2013The California stem cell agency predicts that “human healthcare will be greatly improved” by stem cell research by 2024 and is fleshing out an ambitious plan to help make that happen.
When Will Gene Therapy Come to the U.S.?by Susan YoungMIT Technology ReviewSeptember 30th, 2013Several gene therapies are or will soon be in late-stage human trials. One of them could be the first to get FDA approval for sale in the U.S.
Blinded By Science[Mentions CGS's Jessica Cussins]Center for Environmental HealthSeptember 30th, 2013Three stories of science gone wrong: distorted science, unethical science, and just plain nutty science. We learn about geoengineering, flame retardant chemicals, and the controversy over misuse of Havasupai DNA.
Your Body, Their Propertyby Osagie K. ObasogieBoston ReviewSeptember 30th, 2013When the U.S. Supreme Court struck down human gene patents it took one aspect of the debate over property interests in human biological materials off the table. But other body parts are still considered fair game.
Displaying 744-753 of 1970  
< Prev  Next >> 
« First Page Last Page » 
« Show Complete List » 


ESPAÑOL | PORTUGUÊS | Русский

home | overview | blog | publications| about us | donate | newsletter | press room | privacy policy

CGS • 1936 University Ave, Suite 350, Berkeley, CA 94704 • • (p) 1.510.665.7760 • (F) 1.510.665.8760